Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8D0C

Human SARM1 TIR domain bound to NB-3-ADPR

Summary for 8D0C
Entry DOI10.2210/pdb8d0c/pdb
Related8D0D 8D0E 8D0F 8D0G 8D0H 8D0I 8D0J 8D0M
DescriptorNAD(+) hydrolase SARM1, [[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-[4-[(1~{S})-1-[methyl-[2,2,2-tris(fluoranyl)ethylcarbamoyl]amino]ethyl]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate (3 entities in total)
Functional Keywordsnad, hydrolase, axon degeneration, neuroscience, hydrolase-inhibitor complex, hydrolase/inhibitor
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight34018.25
Authors
Bratkowski, M.A.,Mathur, P. (deposition date: 2022-05-26, release date: 2022-09-21, Last modification date: 2023-10-25)
Primary citationBratkowski, M.,Burdett, T.C.,Danao, J.,Wang, X.,Mathur, P.,Gu, W.,Beckstead, J.A.,Talreja, S.,Yang, Y.S.,Danko, G.,Park, J.H.,Walton, M.,Brown, S.P.,Tegley, C.M.,Joseph, P.R.B.,Reynolds, C.H.,Sambashivan, S.
Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease.
Neuron, 110:3711-, 2022
Cited by
PubMed Abstract: Axon degeneration is an early pathological event in many neurological diseases. The identification of the nicotinamide adenine dinucleotide (NAD) hydrolase SARM1 as a central metabolic sensor and axon executioner presents an exciting opportunity to develop novel neuroprotective therapies that can prevent or halt the degenerative process, yet limited progress has been made on advancing efficacious inhibitors. We describe a class of NAD-dependent active-site SARM1 inhibitors that function by intercepting NAD hydrolysis and undergoing covalent conjugation with the reaction product adenosine diphosphate ribose (ADPR). The resulting small-molecule ADPR adducts are highly potent and confer compelling neuroprotection in preclinical models of neurological injury and disease, validating this mode of inhibition as a viable therapeutic strategy. Additionally, we show that the most potent inhibitor of CD38, a related NAD hydrolase, also functions by the same mechanism, further underscoring the broader applicability of this mechanism in developing therapies against this class of enzymes.
PubMed: 36087583
DOI: 10.1016/j.neuron.2022.08.017
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.09 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon